deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03779230

Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse (GLIOMOON)

A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse

Sponsor: Philogen S.p.A.

Conditions Glioma of Brain
Interventions L19TNF
Updated 10 times since 2019 Last updated: Jun 27, 2023 Started: May 31, 2019 Primary completion: Jun 27, 2023 Completion: Jun 27, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Glioma of Brain, this trial is completed. The trial is conducted by Philogen S.p.A. and has accumulated 10 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshotNot Yet Recruiting~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshotNot Yet Recruiting~Jul 2019 – ~Jan 2021 · 18 months · monthly snapshotRecruiting~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotRecruiting~Feb 2021 – ~May 2022 · 15 months · monthly snapshotRecruiting~May 2022 – ~Jul 2023 · 14 months · monthly snapshotActive Not Recruiting~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. May 2022 — Jul 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 5 earlier versions

  1. Feb 2021 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  2. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jul 2019 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  4. Apr 2019 — Jul 2019 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  5. Jan 2019 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Philogen S.p.A.
Data source: Philogen S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations